Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOZANTINIB Cause Upper respiratory tract infection? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Upper respiratory tract infection have been filed in association with CABOZANTINIB. This represents 0.1% of all adverse event reports for CABOZANTINIB.

5
Reports of Upper respiratory tract infection with CABOZANTINIB
0.1%
of all CABOZANTINIB reports
2
Deaths
4
Hospitalizations

How Dangerous Is Upper respiratory tract infection From CABOZANTINIB?

Of the 5 reports, 2 (40.0%) resulted in death, 4 (80.0%) required hospitalization, and 2 (40.0%) were considered life-threatening.

Is Upper respiratory tract infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABOZANTINIB. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does CABOZANTINIB Cause?

Diarrhoea (404) Fatigue (263) Malignant neoplasm progression (238) Nausea (215) Decreased appetite (191) Off label use (190) Hypertension (165) Pyrexia (162) Vomiting (157) Asthenia (153)

What Other Drugs Cause Upper respiratory tract infection?

ADALIMUMAB (3,306) ETANERCEPT (2,948) TOFACITINIB (1,805) RITUXIMAB (1,713) ABATACEPT (1,623) METHOTREXATE (1,576) TOCILIZUMAB (1,455) APREMILAST (1,437) PREDNISONE (1,354) SECUKINUMAB (1,339)

Which CABOZANTINIB Alternatives Have Lower Upper respiratory tract infection Risk?

CABOZANTINIB vs CABOZANTINIB S-MALATE CABOZANTINIB vs CAFFEINE CABOZANTINIB vs CALASPARGASE PEGOL CABOZANTINIB vs CALASPARGASE PEGOL-MKNL CABOZANTINIB vs CALCIFEDIOL

Related Pages

CABOZANTINIB Full Profile All Upper respiratory tract infection Reports All Drugs Causing Upper respiratory tract infection CABOZANTINIB Demographics